Table 1.
Clinical data of patients
| All patients (no 1026) | |
|---|---|
| Age (years), mean (SD) | 1–18 (7.7 ± 4.34) |
| Female, n (%) | 502 (49.9) |
| Time since last drug reactiona (median) | 1–60 (11) |
| Family history of drug allergy, n (%) | 21(2) |
| of Personal history allergic disease, n (%) | 8 (0.8) |
| Responsible β‐lactams, n (%) | All reactions (no 1066) |
|---|---|
| Amoxicillin | 490 (45.9) [354 + 136 clavulanic acid] |
| Benzylpenicillin | 227 (21.3) |
| Cephalexin | 96 (9) |
| Ampicillin | 55 (5.2) |
| Phenoxymethylpenicillin | 54 (5.1) |
| Ceftriaxone | 46 (4.3) |
| Cefprozil | 43 (4) |
| Cefixime | 40 (3.7) |
| Ceftibuten | 7 (0.7) |
| Cefaclor | 6 (0.6) |
| Cefotaxime | 1 (0.1) |
| Cefuroxime | 1 (0.1) |
| Manifestation, n (%) | All reactions (no 1066) |
|---|---|
| Urticaria | 545 (51.1) |
| Maculopapular exanthema | 423 (39.7) |
| Urticaria plus angioedema | 85 (8) |
| Angioedema | 11 (1) |
| Stevens–Johnson syndrome (SJS) | 2 (0.2) |
| Positive delayed‐reading skin test results, n (%) | All reactions (no 1066) |
|---|---|
| Phenoxymethylpenicillin | 4 (0.4) |
| Benzylpenicillin | 7 (0.7) [2 also patch test positive] |
| Ampicillin | 3 (0.3) |
| Amoxicillin | 28 (2.6) [12 also patch test positive] |
| Cephalexin | 3 (0.3) |
| Cefprozil | 4 (0.4) [1 also patch test positive] |
| Ceftriaxone | 10 (1) [ 2 also patch test positive] |
| Cefixime | 4 (0.4) [1 also patch test positive] |
| Confirmed hypersensitivity after whole allergy work‐up, n (%) | All reactions (no 1066) |
|---|---|
| Phenoxymethylpenicillin | 4 (0.4) |
| Benzylpenicillin | 10 (0.9) |
| Ampicillin | 4 (0.4) |
| Amoxicillin | 38 (3.6) |
| Cephalexin | 5 (0.5) |
| Cefprozil | 5 (0.5) |
| Ceftriaxone | 11 (1.0) |
| Cefixime | 6 (0.6) |
a
Time (months) elapsed between last adverse reaction to β‐lactams and current allergy examination.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.